ArticleJAMA network open2026
Socioeconomic Disparities in Lung Cancer Screening Participation.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Lung cancer screening in high-risk populations reduces mortality, yet the effectiveness of a national screening program depends on equitable participation across socioeconomic and demographic groups. Objective: To investigate whether sociodemographic and socioeconomic factors are associated with participation across stages in a risk-based lung cancer screening pilot program in Sweden. Design, Setting, and Participants: Registry-linked cohort study conducted between September 2022 and May 2024. Participants were women aged 55 to 74 years residing in Region Stockholm, Sweden, who were invited to participate in a pilot program for risk-based lung cancer screening. Exposures: Sociodemographic and socioeconomic factors, including educational level, income, region of origin, and area-level living conditions. Main Outcomes and Measures: Three binary outcomes were examined across sequential stages of the screening pathway: (1) participation in the initial risk-assessment questionnaire, (2) meeting eligibility criteria for low-dose computed tomography (LDCT) screening, and (3) attendance at the LDCT examination among eligible women. Results: Of 34 592 invited women (mean [SD] age, 63.2 [5.6] years), 11 509 (33.3%) completed the questionnaire, 1104 (9.6%) met eligibility criteria, and 980 (88.8%) attended baseline LDCT. Participation in the initial questionnaire was higher among women with higher education (risk ratio [RR], 1.71; 95% CI, 1.59-1.84), higher income (RR, 1.72; 95% CI, 1.64-1.81), and residence in areas with favorable living conditions (RR, 1.59; 95% CI, 1.42-1.79). Conversely, women with higher income (RR, 0.64; 95% CI, 0.54-0.77) and education (RR, 0.38; 95% CI, 0.31-0.46) and those living in socioeconomically advantaged areas (RR, 0.55; 95% CI, 0.43-0.72) were less likely to meet the eligibility criteria for screening with LDCT. Among eligible women, attendance at the LDCT examination was largely equitable, with only minor differences by region of origin. Conclusions and Relevance: In this cohort study, attendance among eligible women was equitable regardless of sociodemographic and socioeconomic profile. However, participation in the initial risk-selection stage was socioeconomically patterned, suggesting that the design of the risk-assessment approach is critical for ensuring equitable access and inclusion of socioeconomically disadvantaged groups in a future national lung cancer screening program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.